5 recruiting. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 5 |
Follow ctDNA: new trials by email Literature Review of ctDNA trials Research Report on ctDNA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ctDNA-guided Treatment Decision-making ADC, Ivonescimab - Metastatic Breast Cancer ( HER2 Negative), ctDNA | Phase 2 | Recruiting | Fudan University | 122 | 2025-12-24 | 2026-02-06 |
| A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer FOLFOX, Folfox plus Bevacizumab - ctDNA, Chemotherapy | Phase 2 | Recruiting | Fudan University | 100 | 2025-04-01 | 2026-05-01 |
| Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer Capecitabine, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - ctDNA, Chemotherapy | Phase 2 | Recruiting | Fudan University | 340 | 2024-11-01 | 2026-05-01 |
| Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer CAPEOX regimen - ctDNA, Colorectal Cancer | Phase 2 | Recruiting | Fudan University | 340 | 2024-11-01 | 2026-05-01 |
| Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer Capecitabine - ctDNA, Colorectal Cancer (CRC) | Phase 2 | Recruiting | Fudan University | 80 | 2024-11-01 | 2026-05-01 |
Colorectal Neoplasms (4) · Breast Neoplasms (1)
Neoplasms (5) · Neoplasms by Site (5) · Colonic Diseases (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Intestinal Diseases (4) · Intestinal Neoplasms (4) · Rectal Diseases (4) · Breast Diseases (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
Capecitabine (2) · Folfox protocol (2) · Bevacizumab (1) · Fluorouracil (1) · Leucovorin (1) · Oxaliplatin (1) · XELOX (1)
Fudan University (5)
China (5)